Compare Boston Scientific Corporation (BSX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Verizon Communications Inc — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Verizon Communications Inc trades at $42.3 (market cap $177.34B). The key difference: Verizon Communications Inc is far larger — about 2.7× Boston Scientific Corporation's market cap, and Verizon Communications Inc pays a 6.66% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | VZ | |
|---|---|---|
Market Cap | $66.37B | $177.34B |
Sector | Health | Media |
52-Week High | $108.14 | $51.38 |
52-Week Low | $42.63 | $38.40 |
Enterprise Value | $75.94B | $364.84B |
Volume | — | 22,584,735 |
Dividend Yield | — | 6.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Verizon (VZ) trades at $42.68, up 1.33% today, with a bearish technical signal from moving averages but recent earnings beats. The stock offers a 6.7% dividend yield with a consensus price target of $47.57, indicating 11.5% upside. Revenue grew to $138.19B in 2025, with a net income margin of 12.46%, while debt levels remain elevated at $144B total debt. Recent news highlights competitive threats from SpaceX's Starlink but also new partnerships like the 5G deal with BMW.
Outlook: VZ presents a value opportunity with a low P/E of 10.4 and strong cash flow, but faces significant competitive and debt-related risks. The stock is suitable for income-focused investors seeking defensive yield, though growth is constrained by industry saturation and rising capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
